NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|66805939|ref|XP_636691|]
View 

arylamine N-acetyltransferase family protein [Dictyostelium discoideum AX4]

Protein Classification

acetyltransferase domain-containing protein( domain architecture ID 1395)

acetyltransferase domain-containing protein may catalyze the transfer of an acetyl group from acetyl-CoA to a substrate; similar to arylamine N-acetyltransferase family proteins

CATH:  3.30.2140.20
EC:  2.3.1.-
SCOP:  4000879

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
Acetyltransf_2 super family cl00949
N-acetyltransferase; Arylamine N-acetyltransferase (NAT) is a cytosolic enzyme of ...
13-296 1.20e-29

N-acetyltransferase; Arylamine N-acetyltransferase (NAT) is a cytosolic enzyme of approximately 30kDa. It facilitates the transfer of an acetyl group from Acetyl Coenzyme A on to a wide range of arylamine, N-hydroxyarylamines and hydrazines. Acetylation of these compounds generally results in inactivation. NAT is found in many species from Mycobacteria (M. tuberculosis, M. smegmatis etc) to man. It was the first enzyme to be observed to have polymorphic activity amongst human individuals. NAT is responsible for the inactivation of Isoniazid (a drug used to treat Tuberculosis) in humans. The NAT protein has also been shown to be involved in the breakdown of folic acid.


The actual alignment was detected with superfamily member COG2162:

Pssm-ID: 470008  Cd Length: 256  Bit Score: 113.05  E-value: 1.20e-29
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939  13 QFFKRIGMKPKPIETLDDVSDVMKACSNVFSFENLDIVSNSCEPLNKDVLIKQVICNNQGGLCYKINTLLYHFLLEFGFK 92
Cdd:COG2162   7 AYLARIGYSGPPAPTLETLRALHRAHVRAIPFENLDVLLGRPISLDPDALFDKLVRRRRGGYCYELNGLFAALLEALGFD 86
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939  93 IHIIRGSVENQETHsDWNIPTGHMINIINFENRLYVVDVAFGCNLSLRPIPITDDgsEVVESCTGLYRVRKVEncvsgky 172
Cdd:COG2162  87 VTLLAARVRWGGPG-GPGPPRTHMALLVTLDGERWLVDVGFGGGTPLEPLPLEDG--TEQDQPGGTYRLVRSD------- 156
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939 173 NYTHILEHRKldsfliesGKTWVTGYAFDPllivdnnnnnektTHQTLV-----QQLVIDDPTKEFSTKPLATKIVNDGs 247
Cdd:COG2162 157 DGEWVLQRRV--------DGGWRPLYRFDL-------------EPQELAdfevaNWYTSTHPDSPFVGNLLVARATPDG- 214
                       250       260       270       280
                ....*....|....*....|....*....|....*....|....*....
gi 66805939 248 sfsIATLTANSFTLTDckTGQKTKTNFDndksSFEQFNQHLISIFNLPP 296
Cdd:COG2162 215 ---RVTLRGRRLTRRR--GGGEEERTLL----SAEELAAVLRERFGLDL 254
 
Name Accession Description Interval E-value
NhoA COG2162
Arylamine N-acetyltransferase [Secondary metabolites biosynthesis, transport and catabolism];
13-296 1.20e-29

Arylamine N-acetyltransferase [Secondary metabolites biosynthesis, transport and catabolism];


Pssm-ID: 441765  Cd Length: 256  Bit Score: 113.05  E-value: 1.20e-29
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939  13 QFFKRIGMKPKPIETLDDVSDVMKACSNVFSFENLDIVSNSCEPLNKDVLIKQVICNNQGGLCYKINTLLYHFLLEFGFK 92
Cdd:COG2162   7 AYLARIGYSGPPAPTLETLRALHRAHVRAIPFENLDVLLGRPISLDPDALFDKLVRRRRGGYCYELNGLFAALLEALGFD 86
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939  93 IHIIRGSVENQETHsDWNIPTGHMINIINFENRLYVVDVAFGCNLSLRPIPITDDgsEVVESCTGLYRVRKVEncvsgky 172
Cdd:COG2162  87 VTLLAARVRWGGPG-GPGPPRTHMALLVTLDGERWLVDVGFGGGTPLEPLPLEDG--TEQDQPGGTYRLVRSD------- 156
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939 173 NYTHILEHRKldsfliesGKTWVTGYAFDPllivdnnnnnektTHQTLV-----QQLVIDDPTKEFSTKPLATKIVNDGs 247
Cdd:COG2162 157 DGEWVLQRRV--------DGGWRPLYRFDL-------------EPQELAdfevaNWYTSTHPDSPFVGNLLVARATPDG- 214
                       250       260       270       280
                ....*....|....*....|....*....|....*....|....*....
gi 66805939 248 sfsIATLTANSFTLTDckTGQKTKTNFDndksSFEQFNQHLISIFNLPP 296
Cdd:COG2162 215 ---RVTLRGRRLTRRR--GGGEEERTLL----SAEELAAVLRERFGLDL 254
Acetyltransf_2 pfam00797
N-acetyltransferase; Arylamine N-acetyltransferase (NAT) is a cytosolic enzyme of ...
44-295 2.64e-23

N-acetyltransferase; Arylamine N-acetyltransferase (NAT) is a cytosolic enzyme of approximately 30kDa. It facilitates the transfer of an acetyl group from Acetyl Coenzyme A on to a wide range of arylamine, N-hydroxyarylamines and hydrazines. Acetylation of these compounds generally results in inactivation. NAT is found in many species from Mycobacteria (M. tuberculosis, M. smegmatis etc) to man. It was the first enzyme to be observed to have polymorphic activity amongst human individuals. NAT is responsible for the inactivation of Isoniazid (a drug used to treat Tuberculosis) in humans. The NAT protein has also been shown to be involved in the breakdown of folic acid.


Pssm-ID: 395644  Cd Length: 240  Bit Score: 95.81  E-value: 2.64e-23
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939    44 FENLDIVSNscEP--LNKDVLIKQVICNNQGGLCYKINTLLYHFLLEFGFKIHIIRGSVENQEThSDWNIPTGHMINIIN 121
Cdd:pfam00797  18 FENLDVHLG--EPisLDLEALFDKLVHKRRGGYCYELNGLFYWVLTELGFDVTLLGGRVYWPRP-GAYSTPQTHLLLLVT 94
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939   122 FENRLYVVDVAFGCNLSLRPIPITddgSEVVESCT-GLYRVRKVEncvsgkyNYTHILEHRKldsfliesGKTWVTGYAF 200
Cdd:pfam00797  95 IDGETYLVDVGFGGSTLWAPLELI---SGKDQPTPhGIFRLVEEG-------GGTWYLEKDG--------RDGWVPLYSF 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939   201 D--PLLIVDNNNNNekTTHQTLvqqlviddPTKEFSTKPLATKIVNDGssfsIATLTANSFTLTDcKTGQKTKTNFDNDk 278
Cdd:pfam00797 157 TlePRQIEDFEVGN--DYLQTS--------PDSHFTTHLLCSRQTPDG----RLTLTGRTLTLRY-KDGALVEIRLLTD- 220
                         250
                  ....*....|....*..
gi 66805939   279 ssfEQFNQHLISIFNLP 295
Cdd:pfam00797 221 ---EEVEDVLKERFGIE 234
 
Name Accession Description Interval E-value
NhoA COG2162
Arylamine N-acetyltransferase [Secondary metabolites biosynthesis, transport and catabolism];
13-296 1.20e-29

Arylamine N-acetyltransferase [Secondary metabolites biosynthesis, transport and catabolism];


Pssm-ID: 441765  Cd Length: 256  Bit Score: 113.05  E-value: 1.20e-29
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939  13 QFFKRIGMKPKPIETLDDVSDVMKACSNVFSFENLDIVSNSCEPLNKDVLIKQVICNNQGGLCYKINTLLYHFLLEFGFK 92
Cdd:COG2162   7 AYLARIGYSGPPAPTLETLRALHRAHVRAIPFENLDVLLGRPISLDPDALFDKLVRRRRGGYCYELNGLFAALLEALGFD 86
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939  93 IHIIRGSVENQETHsDWNIPTGHMINIINFENRLYVVDVAFGCNLSLRPIPITDDgsEVVESCTGLYRVRKVEncvsgky 172
Cdd:COG2162  87 VTLLAARVRWGGPG-GPGPPRTHMALLVTLDGERWLVDVGFGGGTPLEPLPLEDG--TEQDQPGGTYRLVRSD------- 156
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939 173 NYTHILEHRKldsfliesGKTWVTGYAFDPllivdnnnnnektTHQTLV-----QQLVIDDPTKEFSTKPLATKIVNDGs 247
Cdd:COG2162 157 DGEWVLQRRV--------DGGWRPLYRFDL-------------EPQELAdfevaNWYTSTHPDSPFVGNLLVARATPDG- 214
                       250       260       270       280
                ....*....|....*....|....*....|....*....|....*....
gi 66805939 248 sfsIATLTANSFTLTDckTGQKTKTNFDndksSFEQFNQHLISIFNLPP 296
Cdd:COG2162 215 ---RVTLRGRRLTRRR--GGGEEERTLL----SAEELAAVLRERFGLDL 254
Acetyltransf_2 pfam00797
N-acetyltransferase; Arylamine N-acetyltransferase (NAT) is a cytosolic enzyme of ...
44-295 2.64e-23

N-acetyltransferase; Arylamine N-acetyltransferase (NAT) is a cytosolic enzyme of approximately 30kDa. It facilitates the transfer of an acetyl group from Acetyl Coenzyme A on to a wide range of arylamine, N-hydroxyarylamines and hydrazines. Acetylation of these compounds generally results in inactivation. NAT is found in many species from Mycobacteria (M. tuberculosis, M. smegmatis etc) to man. It was the first enzyme to be observed to have polymorphic activity amongst human individuals. NAT is responsible for the inactivation of Isoniazid (a drug used to treat Tuberculosis) in humans. The NAT protein has also been shown to be involved in the breakdown of folic acid.


Pssm-ID: 395644  Cd Length: 240  Bit Score: 95.81  E-value: 2.64e-23
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939    44 FENLDIVSNscEP--LNKDVLIKQVICNNQGGLCYKINTLLYHFLLEFGFKIHIIRGSVENQEThSDWNIPTGHMINIIN 121
Cdd:pfam00797  18 FENLDVHLG--EPisLDLEALFDKLVHKRRGGYCYELNGLFYWVLTELGFDVTLLGGRVYWPRP-GAYSTPQTHLLLLVT 94
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939   122 FENRLYVVDVAFGCNLSLRPIPITddgSEVVESCT-GLYRVRKVEncvsgkyNYTHILEHRKldsfliesGKTWVTGYAF 200
Cdd:pfam00797  95 IDGETYLVDVGFGGSTLWAPLELI---SGKDQPTPhGIFRLVEEG-------GGTWYLEKDG--------RDGWVPLYSF 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 66805939   201 D--PLLIVDNNNNNekTTHQTLvqqlviddPTKEFSTKPLATKIVNDGssfsIATLTANSFTLTDcKTGQKTKTNFDNDk 278
Cdd:pfam00797 157 TlePRQIEDFEVGN--DYLQTS--------PDSHFTTHLLCSRQTPDG----RLTLTGRTLTLRY-KDGALVEIRLLTD- 220
                         250
                  ....*....|....*..
gi 66805939   279 ssfEQFNQHLISIFNLP 295
Cdd:pfam00797 221 ---EEVEDVLKERFGIE 234
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH